3/28/2013

Pharmaceutical firms from Europe, Japan, South Korea and the United States are investing in the development of medications and treatments derived from traditional Chinese medicine. GlaxoSmithKline, for example, recently announced a traditional Chinese medicine program based in Shanghai that will target both a Chinese and global market. "Our priority is to transform TCM from an experience-based practice to evidence-based medicines through innovation and differentiation," said Jingwu Zang, head of R&D for GlaxoSmithKline in China.

Related Summaries